Granzyme K mediates IL-23-dependent inflammation and keratinocyte proliferation in psoriasis

Psoriasis is an inflammatory disease with systemic manifestations that most commonly presents as itchy, erythematous, scaly plaques on extensor surfaces. Activation of the IL-23/IL-17 pro-inflammatory signaling pathway is a hallmark of psoriasis and its inhibition is key to clinical management. Gran...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in immunology Vol. 15; p. 1398120
Main Authors Richardson, Katlyn C, Aubert, Alexandre, Turner, Christopher T, Nabai, Layla, Hiroyasu, Sho, Pawluk, Megan A, Cederberg, Rachel A, Zhao, Hongyan, Jung, Karen, Burleigh, Angela, Crawford, Richard I, Granville, David J
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 05.06.2024
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Psoriasis is an inflammatory disease with systemic manifestations that most commonly presents as itchy, erythematous, scaly plaques on extensor surfaces. Activation of the IL-23/IL-17 pro-inflammatory signaling pathway is a hallmark of psoriasis and its inhibition is key to clinical management. Granzyme K (GzmK) is an immune cell-secreted serine protease elevated in inflammatory and proliferative skin conditions. In the present study, human psoriasis lesions exhibited elevated GzmK levels compared to non-lesional psoriasis and healthy control skin. In an established murine model of imiquimod (IMQ)-induced psoriasis, genetic loss of GzmK significantly reduced disease severity, as determined by delayed plaque formation, decreased erythema and desquamation, reduced epidermal thickness, and inflammatory infiltrate. Molecular characterization revealed that GzmK contributed to macrophage secretion of IL-23 as well as PAR-1-dependent keratinocyte proliferation. These findings demonstrate that GzmK enhances IL-23-driven inflammation as well as keratinocyte proliferation to exacerbate psoriasis severity.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Present address: Christopher T. Turner, Drug Delivery Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, VIC, Australia Future Industries Institute, University of South Australia, Adelaide, SA, Australia; Sho Hiroyasu, Department of Dermatology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan
Christoph Hudemann, Philipps-University Marburg, Germany
Reviewed by: Rachel Basques Caligiorne, Grupo Santa Casa BH, Brazil
Edited by: Haur Yueh Lee, Singapore General Hospital, Singapore
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2024.1398120